Rosetta's miRNA-Based Cancer Tests Break Into European Market through Distribution Deal with AXA

Rosetta Genomics signed up AXA Diagnostics as the distributor for its miRNA-based miRview™ molecular diagnostic cancer tests in Italy. The agreement marks Rosetta’s entry into the European market.

AXA will distribute three miRview tests: miRview for detecting the primary tumor site in patients with metastatic cancer and cancers of unknown primary; miRview squamous, which uses a single miRNA to differentiate between squamous and nonsquamous non-small-cell lung cancer; and miRview meso, which differentiates between the asbestos-related lung cancer called mesothelioma and other lung cancers. 

The company continues to expand its global distribution network and expects that the tests will be available in other countries by the end of this year, says Rosetta’s COO, Ronen Tamir.